ClinicalTrials.gov record
Recruiting Phase 1 Interventional

A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

ClinicalTrials.gov ID: NCT05714072

Public ClinicalTrials.gov record NCT05714072. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 3:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Study of Ruxolitinib Plus Abemaciclib for Patients With Primary or Post-polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Study identification

NCT ID
NCT05714072
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Enrollment
18 participants

Conditions and interventions

Interventions

  • Abemaciclib Drug
  • Ruxolitinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 24, 2023
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026
Last update posted
Nov 17, 2025

2023 – 2027

United States locations

U.S. sites
7
U.S. states
2
U.S. cities
7
Facility City State ZIP Site status
Memorial Sloan Kettering Basking Ridge Basking Ridge New Jersey 07920 Recruiting
Memorial Sloan Kettering Monmouth Middletown New Jersey 07748 Recruiting
Memorial Sloan Kettering Bergen Montvale New Jersey 07645 Recruiting
Memorial Sloan Kettering Suffolk - Commack Commack New York 11725 Recruiting
Memorial Sloan Kettering Westchester Harrison New York 10604 Recruiting
Memorial Sloan Kettering Cancer Center New York New York 10065 Recruiting
Memorial Sloan Kettering Nassau (Limited Protocol Activities) Uniondale New York 11553 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05714072, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 17, 2025 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05714072 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →